Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Cortexyme is a clinical-stage biopharmaceutical company that was developing atuzaginstat (COR388), a small molecule inhibitor targeting Porphyromonas gingivalis, a bacterial pathogen hypothesized to contribute to Alzheimer's disease pathology. Following the Phase 2/3 GAIN trial failure in 2021, the company has pivoted away from Alzheimer's and is exploring alternative indications or strategic options with minimal revenue generation and severe cash burn.
Cortexyme operates as a clinical-stage biotech with no approved products or commercial revenue. The business model historically relied on advancing atuzaginstat through clinical trials to demonstrate efficacy, secure regulatory approval, and either commercialize directly or partner/license the asset to larger pharmaceutical companies. Following the GAIN trial failure, the company is evaluating strategic alternatives including potential asset sales, licensing arrangements, or exploration of alternative therapeutic indications. Value creation depends entirely on clinical data demonstrating differentiated efficacy, which has not materialized. The company has minimal pricing power and faces existential liquidity challenges given negative operating cash flow of approximately $40M+ annually with limited runway.
Clinical trial data readouts or regulatory updates on atuzaginstat or any pivot programs
Strategic transaction announcements (asset sales, licensing deals, merger/acquisition activity)
Cash runway updates and financing announcements (equity raises, debt facilities, dilution risk)
Peer company clinical data in neurodegenerative diseases or infectious disease-related CNS disorders
Management commentary on strategic alternatives and timeline for decision-making
Binary clinical trial risk - single failed Phase 3 trial (GAIN) eliminated primary value driver with no clear path to recovery or alternative validated programs
Alzheimer's disease drug development has exceptionally high failure rates (>99%) with multiple high-profile failures across the industry, creating investor skepticism toward novel mechanisms
Regulatory pathway uncertainty for any pivot indications given lack of established proof-of-concept data
Biotech funding environment deterioration - sustained compression in small-cap biotech valuations and reduced IPO/follow-on offering activity limits capital access
Alzheimer's therapeutic landscape increasingly dominated by anti-amyloid antibodies (Leqembi, Kisunla) with demonstrated efficacy, marginalizing alternative mechanisms like bacterial hypothesis
Large pharmaceutical companies (Eli Lilly, Biogen/Eisai, Roche) have vastly superior resources for neurodegenerative disease R&D and commercialization
Academic and industry research has largely moved away from bacterial causation theories of Alzheimer's following negative clinical data
Critical liquidity risk - current ratio of 1.12 with negative $40M+ annual cash burn suggests runway of potentially less than 12 months without additional financing
Debt/equity ratio of 16.99 indicates heavy debt burden relative to minimal equity value, limiting financial flexibility and increasing bankruptcy risk
Negative ROE of -370.5% and ROA of -135.1% reflect value destruction with no path to profitability under current structure
Equity raise would be massively dilutive at current $100M market cap, potentially requiring reverse split to maintain listing compliance
low - Clinical-stage biotech operations are largely insulated from GDP fluctuations as R&D spending is driven by clinical trial timelines rather than economic conditions. However, financing availability (equity raises, venture funding) becomes more challenging during recessions when risk appetite declines and biotech valuations compress, creating existential liquidity risk for pre-revenue companies.
Rising interest rates negatively impact Cortexyme through multiple channels: (1) higher discount rates compress NPV of distant future cash flows, disproportionately affecting long-duration biotech assets with no near-term revenue; (2) reduced investor appetite for speculative growth stocks as risk-free rates increase; (3) higher opportunity cost makes cash-burning businesses less attractive; (4) tighter venture capital and biotech financing conditions reduce ability to raise capital on favorable terms. The company's negative cash flow makes it highly vulnerable to rate-driven valuation compression.
Moderate - While Cortexyme has minimal traditional credit exposure (no significant receivables or credit-dependent customers), the company's ability to access debt or equity capital markets is critical for survival. Credit market stress and widening high-yield spreads reduce financing options for speculative biotech companies, potentially forcing dilutive equity raises or asset sales at unfavorable valuations. The elevated debt/equity ratio of 16.99 suggests reliance on debt financing which becomes prohibitively expensive or unavailable during credit contractions.
speculative/distressed - The stock attracts highly risk-tolerant investors betting on strategic transaction value, potential asset monetization, or lottery-ticket probability of clinical pivot success. Given the -61.7% one-year return and failed Phase 3 trial, the investor base consists primarily of distressed/special situations funds, biotech-focused hedge funds with high risk tolerance, and retail speculators. Traditional growth or value investors have largely exited. The investment thesis is purely event-driven around strategic alternatives rather than fundamental business performance.
high - Clinical-stage biotechs with failed lead programs exhibit extreme volatility driven by binary news events (financing announcements, strategic transactions, clinical updates). The stock's -61.7% annual return and minimal trading volume at $100M market cap create significant price instability. Beta likely exceeds 2.0x relative to broader biotech indices, with potential for 20-50% single-day moves on material news.
